Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
ANI Pharmaceuticals, Inc.'s quarterly P/E stands at 17.3x. EV/EBITDA has compressed 71.6% YoY to 6.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 25.27 | 17.31 | 20.27 | 45.31 | 24.26 | — | — | — | 20.82 | 353.46 | 29.03 | 40.78 | 158.88 |
| — | — | — | — | +16.5% | — | — | — | -86.9% | — | — | — | — | |
| P/S Ratio | 2.02 | 1.70 | 2.12 | 1.57 | 1.70 | 1.41 | 1.95 | 2.23 | 2.44 | 2.01 | 2.11 | 2.06 | 1.54 |
| — | +20.3% | +8.7% | -29.7% | -30.3% | -29.9% | -7.3% | +8.1% | +58.9% | +15.5% | +34.7% | +26.2% | -12.6% | |
| P/B Ratio | 3.29 | 3.10 | 3.82 | 2.87 | 3.03 | 2.51 | 2.69 | 2.56 | 2.82 | 2.32 | 2.44 | 2.21 | 1.93 |
| — | +23.5% | +42.1% | +12.1% | +7.5% | +8.3% | +10.0% | +15.7% | +45.6% | +19.4% | +56.9% | +54.4% | +47.6% | |
| P/FCF | 9.62 | 64.38 | 12.75 | 4.81 | 22.15 | 20.08 | 37.77 | 23.72 | 24.52 | 6.63 | 10.05 | 17.41 | 8.61 |
| — | +220.6% | -66.3% | -79.7% | -9.7% | +202.9% | +275.8% | +36.3% | +184.9% | — | — | — | — | |
| EV / EBITDA | 8.99 | 6.06 | 10.95 | 11.63 | 9.24 | 21.32 | — | 16.05 | 10.00 | 12.82 | 9.07 | 10.02 | 8.90 |
| — | -71.6% | — | -27.6% | -7.5% | +66.3% | — | +60.2% | +12.4% | -0.3% | -50.2% | -92.8% | — | |
| EV / EBIT | 16.39 | — | 12.93 | 27.08 | 17.82 | — | — | 134.60 | 11.69 | 41.99 | 16.80 | 21.98 | 22.19 |
| — | — | — | -79.9% | +52.4% | — | — | +512.5% | -47.3% | -66.6% | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
ANI Pharmaceuticals, Inc.'s operating margin was 19.5% in Q4 2025, up 9.5 pp QoQ and up 21.8 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 12.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 66.1% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 96.2% | 49.1% | 64.7% | 62.9% | 57.9% | 57.5% | 58.2% | 64.2% | 59.4% | 63.5% | 63.7% | 64.7% |
| — | +66.1% | -14.6% | +11.2% | -2.0% | -2.6% | -9.5% | -8.7% | -0.7% | -3.3% | +4.5% | +22.0% | +38.1% | |
| Operating Margin | 12.6% | 19.5% | 10.0% | 6.6% | 13.3% | -2.3% | -13.8% | 3.7% | 14.8% | 5.1% | 13.6% | 10.6% | 9.3% |
| — | +948.8% | +172.5% | +75.5% | -10.1% | -145.0% | -201.6% | -64.8% | +59.5% | +164.5% | +328.5% | +160.9% | +131.1% | |
| Net Margin | 8.9% | 12.1% | 10.6% | 4.0% | 8.0% | -5.4% | -16.3% | -1.7% | 13.2% | 0.9% | 7.5% | 5.4% | 1.3% |
| — | +325.0% | +165.0% | +344.1% | -40.0% | -714.6% | -316.1% | -130.9% | +883.1% | +119.5% | +173.5% | +126.5% | +104.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.2% | 5.7% | 5.0% | 1.9% | 3.6% | -2.4% | -5.3% | -0.5% | 3.9% | 0.3% | 2.2% | 1.6% | 0.4% |
| — | +339.5% | +194.1% | +495.5% | -7.7% | -1044.5% | -337.2% | -129.6% | +818.0% | +120.1% | +187.6% | +136.9% | +107.4% | |
| ROA | 5.8% | 2.1% | 1.8% | 0.6% | 1.2% | -0.8% | -2.2% | -0.2% | 2.0% | 0.1% | 1.1% | 0.8% | 0.2% |
| — | +363.3% | +180.2% | +360.4% | -39.2% | -721.1% | -292.6% | -132.4% | +960.9% | +122.7% | +198.5% | +138.5% | +107.1% | |
| ROIC | 11.2% | 6.3% | 2.4% | 1.2% | 2.2% | -0.4% | -2.1% | 0.7% | 2.9% | 0.9% | 2.4% | 1.7% | 1.3% |
| — | +1846.5% | +211.7% | +59.8% | -25.4% | -138.3% | -188.0% | -56.1% | +120.6% | +295.3% | +466.3% | +196.0% | +150.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
ANI Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 4.6x, down from 7.1x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.60 | 0.60 | 0.64 | 1.35 | 1.40 | 1.46 | 1.45 | 0.59 | 0.60 | 0.62 | 0.63 | 0.66 | 0.84 |
| — | -58.7% | -56.1% | +126.9% | +134.6% | +133.3% | +130.9% | -9.9% | -29.0% | -26.2% | -26.2% | -22.7% | +1.6% | |
| Debt / EBITDA | 1.61 | 4.59 | 7.10 | 16.72 | 12.69 | 34.25 | — | 14.36 | 8.16 | 13.03 | 8.62 | 10.56 | 11.64 |
| — | -86.6% | — | +16.5% | +55.6% | +162.8% | — | +36.0% | -29.9% | -20.9% | -68.9% | -95.4% | — | |
| Current Ratio | 2.71 | 2.71 | 2.58 | 2.54 | 2.66 | 2.72 | 2.74 | 3.97 | 3.95 | 3.57 | 3.70 | 3.74 | 2.90 |
| — | -0.6% | -5.9% | -35.9% | -32.7% | -23.8% | -25.8% | +6.1% | +36.2% | +3.2% | -2.4% | +11.7% | -23.5% | |
| Quick Ratio | 2.19 | 2.19 | 2.04 | 1.96 | 1.98 | 2.02 | 1.97 | 3.07 | 3.12 | 2.81 | 2.91 | 2.89 | 2.08 |
| — | +8.7% | +3.8% | -36.2% | -36.6% | -28.1% | -32.4% | +6.3% | +50.2% | +16.9% | +11.2% | +21.1% | -24.4% | |
| Interest Coverage | — | 2.11 | 4.83 | 1.69 | 3.23 | -0.73 | -8.80 | 1.11 | 4.42 | 1.17 | 2.81 | 1.75 | 1.29 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ANIP stock.
ANI Pharmaceuticals, Inc.'s current P/E is 25.3x. The average P/E over the last 4 quarters is 26.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ANI Pharmaceuticals, Inc.'s current operating margin is 12.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ANI Pharmaceuticals, Inc.'s business trajectory between earnings reports.